Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1980 1
1981 2
1982 6
1984 2
1985 7
1986 7
1987 1
1988 11
1989 3
1990 3
1992 2
1993 2
1994 3
1995 2
1996 1
1997 1
1999 5
2000 3
2001 3
2002 2
2003 2
2004 10
2005 7
2006 11
2007 12
2008 12
2009 7
2010 6
2011 7
2012 10
2013 12
2014 14
2015 31
2016 30
2017 26
2018 42
2019 39
2020 68
2021 74
2022 68
2023 76
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

573 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Veerashekar
Page 1
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. Flaig TW, et al. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. J Natl Compr Canc Netw. 2022. PMID: 35948037
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. Valle LF, et al. Eur Urol. 2021 Sep;80(3):280-292. doi: 10.1016/j.eururo.2020.11.010. Epub 2020 Dec 11. Eur Urol. 2021. PMID: 33309278 Free PMC article. Review.
Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology.
Glide-Hurst CK, Lee P, Yock AD, Olsen JR, Cao M, Siddiqui F, Parker W, Doemer A, Rong Y, Kishan AU, Benedict SH, Li XA, Erickson BA, Sohn JW, Xiao Y, Wuthrick E. Glide-Hurst CK, et al. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):1054-1075. doi: 10.1016/j.ijrobp.2020.10.021. Epub 2020 Oct 24. Int J Radiat Oncol Biol Phys. 2021. PMID: 33470210 Free PMC article. Review.
Phlebotomy.
Srikanth KK, Lotfollahzadeh S. Srikanth KK, et al. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 34662083 Free Books & Documents.
Advances in MRI-Guided Radiation Therapy.
Chuong MD, Palm RF, Tjong MC, Hyer DE, Kishan AU. Chuong MD, et al. Surg Oncol Clin N Am. 2023 Jul;32(3):599-615. doi: 10.1016/j.soc.2023.02.008. Epub 2023 Apr 4. Surg Oncol Clin N Am. 2023. PMID: 37182995 Review.
Image-guided radiotherapy for prostate cancer.
Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU. Dang A, et al. Transl Androl Urol. 2018 Jun;7(3):308-320. doi: 10.21037/tau.2017.12.37. Transl Androl Urol. 2018. PMID: 30050792 Free PMC article. Review.
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S, Diven MA, Marciscano AE, Zhou XK, Kishan AU, Steinberg ML, Miccio JA, Camilleri P, Nagar H. Wolfe S, et al. BMC Cancer. 2023 Sep 30;23(1):923. doi: 10.1186/s12885-023-11430-z. BMC Cancer. 2023. PMID: 37777738 Free PMC article. Clinical Trial.
The theoretical advantages of MR-guided radiotherapy (MRgRT) have recently been shown to significantly reduce rates of acute grade 2 GU toxicities as reported in the prospective randomized phase III MIRAGE trial, which compared MR-LINAC vs CT-based 5 fraction SBRT in patients wit …
The theoretical advantages of MR-guided radiotherapy (MRgRT) have recently been shown to significantly reduce rates of acute grade 2 GU toxi …
Multimodality Therapies for Localized Prostate Cancer.
Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU. Valle LF, et al. Curr Oncol Rep. 2023 Mar;25(3):221-229. doi: 10.1007/s11912-023-01374-9. Epub 2023 Feb 1. Curr Oncol Rep. 2023. PMID: 36723856 Review.
573 results